Cargando…

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in patients with chronic HBV infection or prior HBV exposure undergoing cytotoxic or immunos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Lok-Ka, Chan, Thomas Sau Yan, Hwang, Yu-Yan, Mak, Lung-Yi, Seto, Wai-Kay, Kwong, Yok-Lam, Yuen, Man-Fung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394758/ https://www.ncbi.nlm.nih.gov/pubmed/37528444 http://dx.doi.org/10.1186/s12985-023-02140-w

Ejemplares similares

New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

The role of different viral biomarkers on the management of chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection
por: Huang, Fung-Yu, et al.
Publicado: (2014)

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022)

The use of transient elastography in the management of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2011)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma
por: Huang, Fung-Yu, et al.
Publicado: (2021)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma
por: Zhang, An-Ye, et al.
Publicado: (2015)

Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2010)

Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
por: Kan, Karin, et al.
Publicado: (2023)

Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese
por: Wong, Danny Ka-Ho, et al.
Publicado: (2013)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
por: Cheung, Ka Shing, et al.
Publicado: (2022)

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
por: Mao, Xianhua, et al.
Publicado: (2023)

Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed
por: Lai, Ching-Lung, et al.
Publicado: (2020)

Carvedilol Versus Other Nonselective Beta Blockers for Variceal Bleeding Prophylaxis and Death: A Network Meta-analysis
por: Cheung, Ka-Shing, et al.
Publicado: (2023)

Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients
por: Cheung, Ka Shing, et al.
Publicado: (2023)

Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance
por: Zheng, Ming-Hua, et al.
Publicado: (2014)

A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2011)

Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2016)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection
por: Wang, Xu, et al.
Publicado: (2018)

Hepatic Pseudolymphoma with an Occult Hepatitis B Virus Infection
por: Kunimoto, Hideo, et al.
Publicado: (2017)

Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction
por: Zhang, Saisai, et al.
Publicado: (2022)

Occult hepatitis B among Iranian hepatitis C patients
por: Shavakhi, Ahmad, et al.
Publicado: (2009)

905. Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National VA Cohort
por: Chen, Ting-Yi, et al.
Publicado: (2021)

Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
por: Lam, Yuk-Fai, et al.
Publicado: (2017)

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
por: Mak, Lung-Yi, et al.
Publicado: (2023)

Seronegative Autoimmune Hepatitis
por: Bhumi, Sriya A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ja7l9s279hbllp46hdmglmq48e